This technique is especially suitable for detection of hotspot alterations, such as MYD88 L265P and CD79B Y196, and already allowed for non-invasive real-time monitoring of disease progression in systemic DLBCL patients [24,25,26]. Here, MYD88 is linked to diffuse large B-cell lymphoma.